Gender and age prevalence distributions of morphea en plaque and anogenital lichen sclerosus

© 2007 The Authors 825 JEADV 2007, 21 , 822–849 Journal compilation © 2007 European Academy of Dermatology and Venereology 2 Hrushesky WJ. Unusual pigmentary changes associated with 5-fluorouracil therapy. Cutis 1980; 26 : 181–182. 3 Falkson G, Schulz EJ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 1962; 74 : 229– 236. 4 Vukelja SJ, Bonner MW, McCollough M et al. Unusual serpentine hyperpigmentation associated with 5fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. J Am Acad Dermatol 1991; 25 : 905–908. 5 Bogenrieder T, Weitzel C, Scholmerich J et al. Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology 2002; 205 : 174–175. 6 Tucker MA, Misfeldt D, Coleman CN et al. Cutaneous malignant melanoma after Hodgkin’s disease. Ann Intern Med 1985; 102 : 37–41. 7 Duvic M, Lowe L, Rapini RP et al. Eruptive dysplastic nevi associated with human immunodeficiency virus infection. Arch Dermatol 1989; 125 : 397–401. 8 Betlloch I, Amador C, Chiner E et al. Eruptive melanocytic nevi in human immunodeficiency virus infection. Int J Dermatol 1991; 30 : 303. 9 Richert S, Bloom EJ, Flynn K, Seraly MP. Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. J Am Acad Dermatol 1996; 35 : 326–329. 10 Fukushima S, Hatta N. Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug. Br J Dermatol 2004; 151 : 698–700.